TY - JOUR T1 - Attentional compensation in neurodegenerative diseases: the model of premanifest Huntington’s disease mutation carriers JF - medRxiv DO - 10.1101/2020.06.03.20121079 SP - 2020.06.03.20121079 AU - Lorna Le Stanc AU - Marine Lunven AU - Maria Giavazzi AU - Agnès Sliwinski AU - Pierre Brugières AU - Katia Youssov AU - Anne-Catherine Bachoud-Lévi AU - Charlotte Jacquemot Y1 - 2020/01/01 UR - http://medrxiv.org/content/early/2020/06/05/2020.06.03.20121079.abstract N2 - The ability of the brain to actively cope with neuropathological insults is known as neural compensation. It explains the delayed appearance of cognitive symptoms in neurodegenerative diseases. In contrast to the neural signature of compensation, its cognitive counterpart is largely unknown due to the difficulty of identifying cognitive dysfunctions concealed by compensation mechanisms. We combined computational modelling and neuroanatomical analysis to explore cognitive compensation. We used Huntington’s disease (HD) as a genetic model of neurodegenerative disease allowing to study compensation in premanifest mutation carriers (preHDs) free from overt cognitive deficits despite incipient brain atrophy.Twenty preHDs, 28 HD patients and 45 controls performed a discrimination task. We investigated the processes underlying cognitive compensation using drift diffusion models. They assume that the discrimination process relies on the accumulation of evidence at a certain rate and terminates when a response threshold is reached.HD patients’ performances were lower than controls’ and explained by a higher response threshold and a lower accumulation rate compared to controls. PreHDs performed similarly to controls but had a response threshold between those of controls and HD patients. This nascent increase in response threshold predicted the accumulation rate, which was faster than controls. This suggests that the higher accumulation rate conceals the nascent deficit in response threshold corroborating the capacity of the brain to resist neuropathological insults in preHDs. The higher accumulation rate was associated with parietal hypertrophy in mutation carriers, and with higher hippocampal volumes in preHDs suggesting that cognitive compensation may rely on attentional capacities.Significance statement Enhancing mechanisms compensating brain degeneration in neurodegenerative diseases might allow to delay their onset and progression. Yet, the cognitive mechanisms of compensation remain to be identified. In order to explore this issue, we used Huntington’s disease as a genetic model of neurodegenerative diseases and combined computational modelling (drift diffusion models) and neuroanatomical data analysis. In the early stage of the disease, before the appearance of overt cognitive symptoms, we showed the involvement of the left superior parietal cortex and hippocampus in maintaining normal behavioural performances. This suggests that attention is used to compensate for brain atrophy early in the disease. This work describes promising means of measuring and understanding compensation mechanisms in neurodegenerative diseases and might help developing new therapies.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis work was supported by the Agence Nationale de la Recherche (ANR-17-EURE-0017, and ANR-11-JSH2-006-1), a grant from Fondation Maladies Rares, programme Sciences Humaines et Sociales & Maladies Rares awarded to Charlotte Jacquemot, a PhD grant from Ecole Doctorale Sciences de la vie et de la sante ED402 awarded to Lorna Le Stanc and an interface contract (Institut National de la Sante Et de la Recherche Medicale - INSERM) awarded to Anne-Catherine Bachoud-Levi. The Henri Mondor Hospital National Reference Centre for Huntington’s Disease funded the follow-up of all the patients included in this study (Ministry of Health).Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Participants were recruited from a clinical biomarker study (NCT01412125) in outpatients approved by the ethics committee of Henri Mondor Hospital (Creteil, France)All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesParticipants signed an informed consent form guaranteeing data confidentiality, and we were therefore unable to share our data through deposition in an open-access repository. However, the data are available, on request, from Prof. Anne-Catherine Bachoud-Levi, for research purposes only. The person requesting the data must sign a confidentiality agreement provided by Assistance Publique-Hopitaux de Paris stipulating that they will make no attempt to identify participants. Given the small size of the cohorts studied, the identification of mutation carriers from center information is feasible. Thus, even with a signed confidentiality agreement, some of the information will be removed, to ensure confidentiality. ER -